Posted on November 8, 2009 by Christopher Little
The French newspaper Le Monde conducted an extensive interview with Sanofi-Aventis Chief Executive Chris Viehbacher about the drug company’s economic survival and whether or not a mega-merger is in order to achieve financial stability. The whole interview isn’t yet available, but in this Dow Jones report about an advance copy, six specific things are [...]
Filed under: C-Level Issues, Emerging Markets Labeling, GS1 | Leave a Comment »
Posted on November 7, 2009 by Christopher Little
Here’s a summary of recent research showing the current and future expected growth of the medical device market in India. It features plenty of stats, all upward trending and at a good velocity, but it was this statement that interested me the most: The medical devices and equipments market is poised for phenomenal growth due [...]
Filed under: C-Level Issues, Emerging Markets Labeling, GS1 | Leave a Comment »
Posted on November 6, 2009 by svigneault
A newly formed organization called the Consumer Electronics Working Action Group (CEWAG), which is an initiative of GS1 Australia, is intended to help
Filed under: C-Level Issues, GS1, GS1 Adoption | Leave a Comment »
Posted on November 5, 2009 by Christopher Little
I go to the U.S. Food and Drug Administration (FDA) website almost every day to glimpse their recent news releases. That’s because sometimes their announcements don’t seem to get much pick up in the usual places. Yesterday they issued this news release. The headline is: FDA Unveils Safe Use Initiative that Targets Preventable Harm from Medication [...]
Filed under: C-Level Issues, FDA related, GS1, Miscellaneous, Patient safety, Pharma | Leave a Comment »
Posted on November 3, 2009 by sterling1
You know, when the subject of barcodes and product labels comes up in many executive suites, C-level executives have a tendency sometimes to tune out. They shouldn’t, of course, because a wrong barcode or an inability to produce labels can stop production and
Filed under: C-Level Issues, GS1 | Leave a Comment »
Posted on November 2, 2009 by Christopher Little
At this site, GS1 Healthcare has made the following announcement: To support the immediate
Filed under: Bar code, C-Level Issues, GS1, Global Standards | Leave a Comment »
Posted on October 30, 2009 by Christopher Little
There are so many voices in a recent news release, posted here by GS1 Healthcare US, it is probably best just to give you the opening paragraph that summarizes everything:
Filed under: C-Level Issues, GS1 | Leave a Comment »
Posted on October 28, 2009 by sterling1
[Editor's note: I have a view which differs from Sterling's even-handed one and certainly from the bias of the two gentlemen quoted below.
Filed under: C-Level Issues, GS1, GS1 Adoption, Global Standards | Leave a Comment »
Posted on October 22, 2009 by sterling1
Here is an important article by Renee Robbins entitled, “Supply chain complexity hampers medical device company operations, compliance,” published by Manufacturing Business Technology.
Filed under: C-Level Issues, supply chain | Leave a Comment »
Posted on October 7, 2009 by sterling1
GS1 recently examined over a million records from four major supermarkets in the UK as well as from Nestle, Unilever, Proctor & Gamble and Mars and you’ll never guess what they found. Here is their very compelling finding about data inconsistencies GS1 believes will cost UK grocery retailers £1 billion over the next five years if [...]
Filed under: C-Level Issues, GS1, GS1 Adoption, Global Standards | Leave a Comment »
Posted on September 29, 2009 by Christopher Little
Big news: In an email today from John Roberts, Director, GS1 Healthcare US, we’re being informed that at a recent seminar in China conducted by AdvaMed, which is a major association of advanced medical technology producers, officials representing the China State Food and Drug Administration (SFDA) said they plan to follow the
Filed under: C-Level Issues, FDA related, GS1, GS1 Adoption, Track & Trace | Leave a Comment »
Posted on September 29, 2009 by Christopher Little
In an online story from the UK’s Financial Times, writer Marko Dimitrijevic says this: The term emerging markets is obsolete. They represent half of the world’s economy; their financial markets are large and liquid, with volatility, corporate governance and government policies very similar to those of developed markets. The traditional distinctions between emerging and developed markets, once [...]
Filed under: C-Level Issues, Emerging Markets Labeling, FDA related, GS1 | Leave a Comment »
Posted on September 27, 2009 by sterling1
Brazil is the “B” in the shorthand for emerging markets sometimes lumped together as BRIC. Quite often here we’ve been covered news for two simultaneous points: emerging markets offer tremendous growth opportunities during this period of economic malaise in developed countries and, two, these emerging markets are making important contributions to the adoption and enforcement [...]
Filed under: C-Level Issues, Emerging Markets Labeling, GS1 | Leave a Comment »
Posted on September 22, 2009 by Christopher Little
Editor’s note: As an editorial decision since the inception of this blog, I’ve steered away from Loftware promotional posts. The panel session cited above, in my opinion, is news and the fact Loftware is in the middle of it, well, does it lose its news worthiness and become an ad? No, I don’t think so.
Announced [...]
Filed under: C-Level Issues, FDA related, GS1, GS1 Adoption, Global Standards, Miscellaneous | 2 Comments »
Posted on September 16, 2009 by Christopher Little
In a news release today, the Premier Healthcare Alliance, which represents more than 2,200 U.S. hospitals and 63,000-plus other healthcare sites, announced upcoming presentations its senior executives will be making around the country in the coming days and months. Premier, you’ll recall, was the first group purchasing organization to endorse the use of GS1 supply [...]
Filed under: C-Level Issues, GS1, Global Standards, HL7 | Leave a Comment »
Posted on September 11, 2009 by Christopher Little
The headline on this Wall Street Journal article not only says it all, but validates the emerging markets focus we’ve been featuring here for months.
Filed under: C-Level Issues, Emerging Markets Labeling, GS1 | Leave a Comment »
Posted on September 8, 2009 by Christopher Little
This news crossed Business Wire about an hour ago:
The emerging markets are luring a growing number of pharma companies looking to compensate for the diminishing revenues in developed markets. Latin America and Central and Eastern Europe (CEE) are showing strong growth rates, proving to be lucrative targets for firms aiming to expand their foothold, initially [...]
Filed under: C-Level Issues, Emerging Markets Labeling, GS1 | Leave a Comment »
Posted on September 6, 2009 by sterling1
Viet Nam News may be a rather unusual source of information, but featured here in this article is
Filed under: C-Level Issues, Emerging Markets Labeling, GS1 | Leave a Comment »
Posted on September 2, 2009 by Christopher Little
This is the first of several planned posts about a major healthcare technology panel at Oracle OpenWorld 2009 in San Francisco (where Loftware will also be exhibiting in booth 3108, West Exhibition Hall). While Oracle’s chief focus this year at the October show is rightfully on their formal launch yesterday of 11g Release 2 of its database, [...]
Filed under: C-Level Issues, FDA related, GS1, Global Standards | Leave a Comment »
Posted on August 31, 2009 by sterling1
A major conference of regulatory affairs professionals
Filed under: C-Level Issues, GS1 | Leave a Comment »